On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM). Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy.
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.